Ladera Closure System Shows 98% Freedom From Complications

Full FASTEN trial results for the investigational Ladera Large Bore Closure System were announced by Ladera Medical.

Updated on Nov. 22, 2026 in Healthcare

Bold flat-color editorial illustration of two parallel threads drawn across the opening of a tubular vessel beside a small spool, conveying a medical closure device.
Ladera Medical reported that its Ladera Large Bore Closure System achieved 98.1% freedom from major access-site complications at 30 days in the 55-patient FASTEN trial, though the device remains investigational. AI Illustration. Upload story photo >

Ladera Medical announced full results from the FASTEN clinical trial of its Ladera Large Bore Closure System, which enrolled 55 patients at six sites in Australia, Belgium, and the Netherlands. The device achieved 98.1% freedom from major access-site complications at 30 days.

Why it matters

Existing suture devices were designed for small bore punctures and typically require two or more devices per access site, so a single system closing larger arteriotomies addresses a recognized gap. The device remains limited by federal law to investigational use and is not available for sale in any country.

Mean time to hemostasis was 0.5 ± 2.0 minutes and mean time to ambulation was 14.3 ± 14.5 hours across the 55 enrolled patients. The device closes arteriotomies from 10F to 24F, though the study does not report outcomes for every size in the range.

The players

Ladera Medical

Ladera Medical is a medical technology company headquartered in Menlo Park, California, that develops vascular closure devices.

Jan van der Heyden, MD

Jan van der Heyden, MD is a physician at a hospital in Bruges, Belgium, who presented the FASTEN trial data at London Valves 2026.

The details

The Ladera System deploys two parallel sutures simultaneously to close femoral arterial access sites and can be used either before a procedure (pre-close) or after it (post-close) while maintaining guidewire access. Preliminary FASTEN results were presented at EuroPCR 2026, and full data were presented by Jan van der Heyden, MD in a Late-Breaking Clinical Trials session at London Valves 2026.

Timeline

  1. EuroPCR 2026: preliminary FASTEN results presented.

  2. November 22, 2026: Ladera Medical announced full FASTEN results.

  3. London Valves 2026: full FASTEN data presented in a Late-Breaking Clinical Trials session.

Market Landscape

Conventional suture devices were built for small-bore punctures and often need two or more devices per access site, so the Ladera System positions itself as a single-device option for larger femoral access sites. Its investigational status means it has not yet entered the commercial vascular closure market.

Because the Ladera System remains investigational and is not available for sale in any country, patients cannot currently access it outside clinical trials. Clinicians and patients should rely on approved closure options until regulatory availability is established.

The takeaway

Large-bore access closure is an area of active innovation, and a single device closing arteriotomies up to 24F could simplify procedures once it reaches the market. Readers should watch for regulatory decisions before expecting clinical availability.

Further reading

Explore more on Healthcare developments in medical devices and clinical research.

Source note: This article includes information reported by The Queenslander.